BTIG analyst Thomas Shrader raised the firm’s price target on NRx Pharmaceuticals (NRXP) to $25 from $21 and keeps a Buy rating on the shares. The company is making progress on most fronts, and with FDA acceptance for the NDA detailing preservative-free ketamine, on-label option for MDD, Major Depressive Disorder, and ASIB, Acute Suicidal Ideation and Behavior, is the next important event, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- Psychedelic: NRx Pharmaceuticals reports Q2 earnings
- NRx Pharmaceuticals Reports Progress in Drug Development Amid Financial Challenges
- NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs
- Nrx Pharmaceuticals Faces Financing Hurdles in Strategic Acquisitions of Kadima and Dura Medical
- NRX Pharmaceuticals Secures $6.5 Million Investment